about
Targeting folate receptor alpha for cancer treatmentCancer immunotherapy: the beginning of the end of cancer?Immunotherapy and radiation therapy for malignant pleural mesothelioma.Enrichment of Inflammatory IL-17 and TNF-α Secreting CD4(+) T Cells within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1Opportunities and challenges in combination gene cancer therapy.Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.Potential role of immunotherapy in advanced non-small-cell lung cancerIs autoimmunity the Achilles' heel of cancer immunotherapy?New challenges in therapeutic vaccines against HIV infection.New agents on the horizon in gastric cancer.High-throughput genomic profiling of tumor-infiltrating leukocytes.An update on clinical oncology for the non-oncologist.Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.Metabolic Instruction of Immunity.Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds.Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.Clinical trials of CAR-T cells in ChinaActivity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.Implications of the tumor immune microenvironment for staging and therapeutics.Nivolumab-induced aplastic anemia: A case report and literature review.The dawn of "immune-revolution" in children: early experiences with checkpoint inhibitors in childhood malignancies.Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.Genetic mechanisms of immune evasion in colorectal cancer.The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease.Effects of Affordable Care Act Marketplaces and Medicaid Eligibility Expansion on Access to Cancer Care.[Renaissance of immuno-oncology for urological tumors : Current status].Current status and future directions of cancer immunotherapy.CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies.PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancerCytokine release syndrome: grading, modeling, and new therapy
P2860
Q26744215-52B4651C-E7EA-4583-8878-B394FF9AC515Q26752277-EE8AD096-4128-4C79-8C84-4A17D516DD6EQ33645613-6477EA3A-CECE-4BBD-A0BD-DD1816A70B80Q36658129-48078683-D7C5-4967-ACAE-2CE1185368BCQ37118663-010EF0F3-1D2E-4F99-8359-84909EF4D67DQ37264931-63C06155-CB49-4D27-8F70-9BCF730AE810Q37527869-18628558-2C5B-4E7D-843D-DE9A9E9A3417Q38687375-D973CB4D-0357-448A-8739-F88AE1170466Q38692205-17A2837F-8DD6-48A6-A5CC-0BB28BA20D9DQ38759129-C57A1B73-513F-4E6C-BD25-7BD013D919B3Q38884388-1195ABBF-D193-45BA-80D6-0614C428E013Q38909979-78C5C47D-4A8C-4C64-B6F7-CE8B189D33EEQ38916529-06B65EE1-7313-4140-BA7A-AEF23226ED02Q38919707-D041BDA0-7941-4B58-A9B2-81BE129CE0B9Q39085984-A67420FB-EB6D-47FA-B333-12C328707723Q39286043-A5633961-9C9E-44AB-B0C7-D416DA647129Q41078784-ECD089F1-4030-477A-9295-EB89808E5033Q41628716-A404E467-D6CE-4E39-8583-837058D291BDQ42269519-42854AE3-25DB-4BF3-AE79-4D3F6C8E6AD4Q42375254-0069411E-5A57-4514-B129-5EDD2E113A5BQ42654456-EF653005-900E-4C58-8416-7EBCB51377C7Q47151168-C1D64361-2EE4-4788-AA6B-0E2FDCC48DE4Q47569563-545CF952-2624-49AA-9AB8-5881CEFE6A97Q47592007-77F364A6-1EF0-443F-B760-3DCAEF48B9BCQ47663335-4188CB5B-5D37-46FE-B33A-AE0408FADC6FQ47724505-BB082815-319E-4DC3-A8DD-DF5F4DF577ECQ48507489-33A759EE-87EA-4F36-BDFD-2C17DA96E284Q50420634-285758C3-3CA3-42E8-8F8A-6E13772F7178Q51538499-A278FB4C-6EE6-4C5C-8DDE-6DEB14A5CA08Q52866342-979C681B-187A-41C1-A2A6-763E4439BF9CQ53113766-DBD680E7-6D59-46BF-BD1F-72DE9B5C7679Q55070491-6091F1CC-EAB1-4CF6-B0E9-89B072490367Q55193924-0EE7D136-4EBA-4EA7-A9B6-48E1C9528CEFQ57073426-DF025A55-C896-44FA-94E4-3F31A5B1DBD6Q58700983-5BA0E912-30D1-4649-A7AB-C087EAEA29CE
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Releasing the Brakes on Cancer Immunotherapy.
@en
Releasing the Brakes on Cancer Immunotherapy.
@nl
type
label
Releasing the Brakes on Cancer Immunotherapy.
@en
Releasing the Brakes on Cancer Immunotherapy.
@nl
prefLabel
Releasing the Brakes on Cancer Immunotherapy.
@en
Releasing the Brakes on Cancer Immunotherapy.
@nl
P356
P1476
Releasing the Brakes on Cancer Immunotherapy.
@en
P2093
Antoni Ribas
P304
P356
10.1056/NEJMP1510079
P407
P577
2015-09-08T00:00:00Z